


References

1. Bouma G, Ancliff PJ, Thrasher AJ, Burns SO (2010) Recent advances in the understanding of genetic defects of neutrophil number and function. *Br J Haematol* 151:312–326
2. Navarini AA, Lang KS, Verschoor A et al (2009) Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. *Proc Natl Acad Sci USA* 106:7107–7112
3. Raffaghello L, Bianchi G, Bertolotto M et al (2008) Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. *Stem Cells* 26:151–162
4. Babior B (2001) Production, distribution and fate of neutrophils. McGraw-Hill, New York, pp 753–759
5. Nauseef WM (2007) How human neutrophils kill and degrade microbes: an integrated view. *Immunol Rev* 219:88–102
6. Rogers HW, Unanue ER (1993) Neutrophils are involved in acute, nonspecific resistance to *Listeria monocytogenes* in mice. *Infect Immun* 61:5090–5096
7. Rakhmilevich AL (1995) Neutrophils are essential for resolution of primary and secondary infection with *Listeria monocytogenes*. *J Leukoc Biol* 57:827–831
8. Lundqvist-Gustafsson H, Bengtsson T (1999) Activation of the granule pool of the NADPH oxidase accelerates apoptosis in human neutrophils. *J Leukoc Biol* 65:196–204
9. Peled A, Wald O, Burger J (2012) Development of novel CXCR4-based therapeutics. *Expert Opin Investig Drugs* 21:341–353
10. Hendrix CW, Flexner C, MacFarland RT et al (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. *Antimicrob Agents Chemother* 44:1667–1673
11. Ichiyama K, Yokoyama-Kumakura S et al (2003) A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. *Proc Natl Acad Sci USA* 100:4185–4190
12. Murakami T, Kumakura S, Yamazaki T et al (2009) The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. *Antimicrob Agents Chemother* 53:2940–2948
13. Murakami T, Yamamoto N (2010) Role of CXCR4 in HIV infection and its potential as a therapeutic target. *Future Microbiol* 5:1025–1039
14. Shinohara K, Sakai K, Ando S et al (1999) A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. *J Gen Virol* 80:1231–1240
15. Kaizu M, Ami Y, Nakasone T et al (2003) Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV. *Virology* 313:8–12
16. Nakasone T, Sakai K, Ami Y et al (2002) Genetic and biological characterization of a highly pathogenic molecular clone, SHIV-C2/1 KS661. *J Med Primatol* 31:277
17. Nakasone T, Kanekiyo M, Yoshino N et al (2007) Cell-associated SHIV infection in cynomolgus monkeys. *J Med Primatol* 36:308–309
18. Ami Y, Izumi Y, Matsuo K et al (2005) Priming-boosting vaccination with recombinant *Mycobacterium bovis* bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. *J Virol* 79:12871–12879
19. Murakami T, Eda Y, Nakasone T et al (2009) Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4⁺ T-cell loss in macaque lymphoid tissue. *AIDS* 23:1485–1494
20. Someya K, Xin KQ, Ami Y et al (2007) Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. *Virology* 367:390–397
21. Motohara M, Ibuki K, Miyake A et al (2006) Impaired T-cell differentiation in the thymus at the early stages of acute pathogenic chimeric simian-human immunodeficiency virus (SHIV) infection in contrast to less pathogenic SHIV infection. *Microbes Infect* 8:1539–1549
22. Miyake A, Ibuki K, Enose Y et al (2006) Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. *J Gen Virol* 87:1311–1320
23. Matsuda K, Inaba K, Fukazawa Y et al (2010) In vivo analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. *Virology* 399:134–143
24. Lu Y, Salvato MS, Pauza CD et al (1996) Utility of SHIV for testing HIV-1 vaccine candidates in macaques. *J Acquir Immune Defic Syndr Hum Retrovirol* 12:99–106
25. Nakasone T, Murakami T, Yamamoto N (2012) Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic SHIV infection in macaques. *Jpn J Infect Dis* 65(4)
26. De Clercq E (2010) Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, MozobilTM) and potential of other CXCR4 antagonists as stem cell mobilizers. *Pharmacol Ther* 128:509–518
27. Chow KY, Brotin É, Ben Khalifa Y et al (2010) A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome. *Cell Host Microbe* 8:523–533



Pharmacophore-based small molecule CXCR4 ligands

Tetsuo Narumi^a, Tomohiro Tanaka^a, Chie Hashimoto^a, Wataru Nomura^a, Haruo Aikawa^a, Akira Sohma^a, Kyoko Itotani^a, Miyako Kawamata^b, Tsutomu Murakami^b, Naoki Yamamoto^c, Hirokazu Tamamura^{a,*}

^aInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan

^bAIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan

^cYong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore

ARTICLE INFO

Article history:

Received 16 March 2012

Revised 4 April 2012

Accepted 7 April 2012

Available online 20 April 2012

Keywords:

HIV entry inhibitors

Chemokine receptor

AIDS

Low molecular weight CXCR4 ligands

ABSTRACT

Low molecular weight CXCR4 ligands were developed based on the peptide T140, which has previously been identified as a potent CXCR4 antagonist. Some compounds with naphthyl, fluorobenzyl and pyridyl moieties as pharmacophore groups in the molecule showed significant CXCR4-binding activity and anti-HIV activity. Structure–activity relationships were studied and characteristics of each of these three moieties necessary for CXCR4 binding were defined. In this way, CXCR4 ligands with two types of recognition modes for CXCR4 have been found.

© 2012 Elsevier Ltd. All rights reserved.

The chemokine receptor CXCR4 is classified into a family of G protein-coupled receptors (GPCRs), and transduces signals of its endogenous ligand, CXCL12/stromal cell-derived factor-1 (SDF-1).¹ The CXCR4–CXCL12 axis plays a physiological role in chemotaxis,² angiogenesis³ and neurogenesis⁴ in embryonic stages. The CXCR4 receptor is linked to many disorders including HIV infection/AIDS,⁵ metastasis of cancer cells,⁶ leukemia cell progression,⁷ rheumatoid arthritis.⁸ Since CXCR4 is an important drug target in these diseases, it is thought that effective agents directed to this receptor may be useful leads for therapeutic agents. To date, we and others have developed several potent CXCR4 antagonists. A highly potent antagonist, T140, a 14-mer peptide with a disulfide bridge, and its downsized analogue, FC131, with a cyclic pentapeptide scaffold, and several other related compounds have been reported.⁹ Based on T140 and FC131, small-sized linear anti-HIV agents such as ST34 (**1**) have been developed (Fig. 1).¹⁰ AMD3100,¹¹ KRH-1636,¹² Dpa–Zn complex (**2**)¹³ and other azamacrocyclic compounds such as **3**,¹⁴ which like **1**, contain benzylamine and electron-deficient aromatic groups, have also been reported as nonpeptidic antagonists. Compound **1** possesses significant anti-HIV activity but does not have high CXCR4 binding affinity. In the present study, more effective linear CXCR4 antagonists derived from compound **1** have been examined, and structure–activity relationship studies of these compounds have been performed.

Initially, three segments of compound **1** were selected for structural modification to support the design of new synthetic compounds: replacement of the 4-trifluoromethylbenzoyl group (Fig. 2, R¹), modification of the stereochemistry of the 1-naphthylethylamine moiety (R²) and introduction of pyridine moieties on the nitrogen atom (R³). In a previous study of T140 analogues, 4-fluorobenzoyl was found to be superior to 4-trifluoromethylbenzoyl as an N-terminal moiety. Thus, 4-fluorobenzyl, 4-fluorobenzoyl and 4-fluorophenylethyl groups were used as substitutes for the 4-trifluoromethylbenzoyl group (R¹) in **1**. The (R)-1-naphthylethylamine moiety in **1** is also present in KRH-1636 where it has the (S)-stereochemistry and thus both the (R) and (S)-stereoisomers were investigated in the present study. Several CXCR4 antagonists such as KRH-1636,¹² Dpa–Zn complex (**2**)¹³ and Dpa-cyclam compound (**3**),¹⁴ contain pyridyl rings. Thus, 2, 3, or 4-pyridylmethyl and 2, 3, or 4-pyridylethyl groups were introduced on the nitrogen atom of the 4-aminomethylbenzoyl group (R³). With these modifications, a total of 3 × 2 × 6 = 36 compounds (**12–47**) were designed (Fig. 2).

The synthesis of the structural fragment, Unit 1 is shown in Scheme 1. N-nosylation of 4-amino-methylbenzoic acid (**4**) with 2-nitrobenzenesulfonyl chloride and subsequent esterification gave the *t*-butyl ester **5**. Introduction of an R³ moiety by means of a Mitsunobu reaction followed by removal of the Ns group yielded amines **6A–F**. Introduction of either 4-fluorobenzyl or 4-fluorophenylethyl groups by reductive amination of **6A–F** produced amines **7Ai–Fi** or **7Aii–Fii**, respectively. Conversion of **6A–F** to the appropriate amide (**7Aii–Fii**), and subsequent deprotection of the *tert*-butyl group yielded Unit 1, **8Ai–Fiii**.

* Corresponding author.

E-mail address: tamamura.mr@tmd.ac.jp (H. Tamamura).




Figure 1. The structures of **1** (ST34), Dpa-Zn complex (**2**) and Dpa-cyclam compound (**3**).






Figure 2. The structures of substituents for three parts of compound **1** in the design of new compounds.




Scheme 1. The synthetic scheme of Unit 1, compounds **8Ai-Fiii**. Reagents and conditions and yields: (a) NscI , Et_3N , $\text{THF}/\text{H}_2\text{O}$ (1/1); (b) isobutene, $\text{THF}/\text{H}_2\text{SO}_4$ (10/1), 39% (2 steps); (c) PPh_3 , DEAD , R^2OH , THF ; (d) PhSH , K_2CO_3 , DMF , 42–92% (2 steps); (e) $\text{NaBH}(\text{OAc})_3$, 4-fluorobenzaldehyde, CH_2Cl_2 ; (f) $\text{NaBH}(\text{OAc})_3$, (4-fluorophenyl)acetaldehyde, CH_2Cl_2 ; (g) 4-fluorobenzoyl chloride, Et_3N , CH_2Cl_2 , 51–94%; (h) TFA then 4 M HCl/EtOAc , quantitative; The structures of R^1 and R^3 are shown in Fig. 2 as i–iii and A–F, respectively. Ns = 2-nitrobenzenesulfonyl, tBu = *tert*-butyl, DEAD = diethyl azodicarboxylate.

The synthesis of Unit 2 is shown in Scheme 2. Condensation of Boc-Arg(Mts)-OH (**9**) and (*R/S*)-(+/-)-1-(1-naphthyl)ethylamine, CH_2Cl_2 , 83–97%; (j) TFA then 4 M HCl/EtOAc , quantitative; EDCl-HCl = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, $\text{HOBT}\cdot\text{H}_2\text{O}$ = 1-hydroxybenzotriazol monohydrate, Mts = 2,4,6-trimethylphenylsulfonyl, Boc = *tert*-butoxycarbonyl.

Compounds **12–47** were synthesized by amide condensation of Unit 1, **8Ai-Fiii**, with Unit 2, (*R*)-**11** and (*S*)-**11**, and subsequent deprotection of the Mts group, as shown in Scheme 3.¹⁵ All the synthetic compounds were purified by preparative reverse phase HPLC. In cases where peaks derived from side products appeared around the target peaks on the HPLC profile, the precise analysis was accomplished, giving rise to lower yields (Scheme 3, 1).



Scheme 2. Synthetic schemes of Unit 2, compounds (*R/S*)-**11**. Reagents and conditions: (i) EDCl-HCl, $\text{HOBT}\cdot\text{H}_2\text{O}$, Et_3N , (*R/S*)-(+/-)-1-(1-naphthyl)ethylamine, CH_2Cl_2 , 83–97%; (j) TFA then 4 M HCl/EtOAc , quantitative; EDCl-HCl = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, $\text{HOBT}\cdot\text{H}_2\text{O}$ = 1-hydroxybenzotriazol monohydrate, Mts = 2,4,6-trimethylphenylsulfonyl, Boc = *tert*-butoxycarbonyl.



Scheme 3. Synthetic schemes of compounds **12–47**. Reagents and conditions: (k) EDCl-HCl, $\text{HOBT}\cdot\text{H}_2\text{O}$, Et_3N , DMF , 36–95%; (l) TMSBr, *m*-cresol, 1,2-ethanedithiol, thioanisole, TFA, 4–54%. The structures of R^1 and R^3 are shown in Figure 2 as i–iii and A–F, respectively.

The CXCR4-binding activity of synthetic compounds was assessed in terms of the inhibition of [¹²⁵I]-CXCL12 binding to Jurkat cells, which express CXCR4.¹⁶ The percent inhibition of all the compounds at 10 μM is shown in Table 1. Several of the compounds showed significant binding affinity. In general, compounds in which the 1-naphthylethylamine moiety (R^2) has the (*S*)-stereochemistry, as in KRH-1636, are more potent than the (*R*)-stereoisomers. Ten compounds (**26–28**, **30**, **33**, **36**, **39**, **44**, **45** and **47**, Table 1) were found to induce at least 30% inhibition and compounds **26**, **27** and **33**, which have a pyridyl group with a nitrogen atom at the β -position, showed more than 60% inhibition. It is noteworthy that compounds **26** and **27** in which R^2 is a (*R*)-1-naphthylethylamine moiety, are both more potent than the corresponding (*S*)-stereoisomers **44** and **45**. Compounds **26**, **27** and **33**, have a 4-fluorobenzyl or 4-fluorophenylethyl group, which rather than an amide, is a reductive alkyl type (R^1). As can be seen from Table 1, there is a tendency for compounds with a pyridyl group with a nitrogen atom at the β -position (R^3 : C or D), to be more potent in CXCR4-binding activity than the corresponding compounds, which have a pyridyl group with a nitrogen atom at the α - or γ - position (R^3 : A, B, E or F), and those with a reductive alkyl 4-fluorobenzyl or 4-fluorophenylethyl group (R^1 : i or iii), to be more potent in CXCR4-binding activity than the corresponding compounds, with a 4-fluorobenzoyl group (R^1 : ii).

Compounds were next evaluated for anti-HIV activity and cytotoxicity. CXCR4 is the major co-receptor for the entry of T-cell line-tropic (X4-) HIV-1.⁵ Accordingly, inhibitory activity against X4-HIV-1 (NL4-3 strain)-induced cytopathogenicity in MT-4 cells (anti-HIV activity), and reduction of the viability in MT-4 cells (cytotoxicity) were assessed¹⁶ and are shown in Table 1. Compounds **26** and **33–35** showed significant anti-HIV activity with EC_{50} values in the micromolar range. Compounds **26** and **33** showed both potent CXCR4-binding activity (79% and 60% inhibition at 10 μM , respectively) and anti-HIV activity (EC_{50} = 11 and 13 μM , respectively), the two activities being highly correlated. Compounds **34** and **35** have significant anti-HIV activity with EC_{50} values of 8 and 10 μM , respectively, which is higher than CXCR4-binding activities, which are 16% and 20% inhibition at 10 μM , respectively. Compound **27**, which showed relatively high CXCR4-binding activity (69% inhibition at 10 μM), failed to show

Table 1
CXCR4-binding activity, anti-HIV activity and cytotoxicity of compounds **12–47**

Compd no.	R ¹ ^a	R ² ^b	R ³ ^c	Inhibition ^d (%)	EC ₅₀ ^e (μM)	CC ₅₀ ^f (μM)	Compd no.	R ¹ ^a	R ² ^b	R ³ ^c	Inhibition ^d (%)	EC ₅₀ ^e (μM)	CC ₅₀ ^f (μM)
12	i	(R)	A	0	>20	35	30	i	(S)	A	30 ± 1.1	>4	11
13	i	(R)	B	4 ± 1.7	>4	23	31	i	(S)	B	25 ± 3.3	>20	24
14	i	(R)	C	6 ± 0.7	>20	37	32	i	(S)	C	27 ± 1.7	>20	41
15	i	(R)	D	24 ± 1.7	n.d.	n.d.	33	i	(S)	D	60 ± 1.5	13	65
16	i	(R)	E	12 ± 3.0	>20	39	34	i	(S)	E	16 ± 1.2	8	44
17	i	(R)	F	16 ± 2.2	n.d.	n.d.	35	i	(S)	F	20 ± 1.3	10	44
18	ii	(R)	A	3 ± 0.9	>20	38	36	ii	(S)	A	36 ± 1.8	>20	37
19	ii	(R)	B	6 ± 3.9	>20	41	37	ii	(S)	B	0	>20	43
20	ii	(R)	C	11 ± 0.8	>20	45	38	ii	(S)	C	14 ± 1.4	>20	57
21	ii	(R)	D	22 ± 4.1	n.d.	n.d.	39	ii	(S)	D	32 ± 8.4	n.d.	n.d.
22	ii	(R)	E	6 ± 2.7	>20	45	40	ii	(S)	E	13 ± 1.5	>20	51
23	ii	(R)	F	12 ± 1.9	n.d.	n.d.	41	ii	(S)	F	25 ± 1.3	>20	47
24	iii	(R)	A	15 ± 2.1	n.d.	n.d.	42	iii	(S)	A	16 ± 5.1	>4	9.9
25	iii	(R)	B	13 ± 0.6	>20	27	43	iii	(S)	B	23 ± 1.4	>4	13
26	iii	(R)	C	79 ± 14	11	47	44	iii	(S)	C	36 ± 1.3	n.d.	n.d.
27	iii	(R)	D	69 ± 5.0	>11	11	45	iii	(S)	D	35 ± 5.2	n.d.	n.d.
28	iii	(R)	E	44 ± 5.4	n.d.	n.d.	46	iii	(S)	E	26 ± 2.3	n.d.	n.d.
29	iii	(R)	F	0	n.d.	n.d.	47	iii	(S)	F	51 ± 6.6	n.d.	n.d.
KRH-1636				100	0.33	80	FC131				100	0.16	>10
AMD3100				n.d.	0.062	55	1 (ST34)				n.d.	7.4	66
AZT				n.d.	0.058	100							

^{a,c} The structures of R¹ and R³ are shown in Fig. 2 as i–iii and A–F, respectively.

^b The absolute configuration in stereochemistry of R² shown in Fig. 2 is described.

^d CXCR4-binding activity was assessed based on the inhibition of the [¹²⁵I]-CXCL12 binding to Jurkat cells. Inhibition percentages of all the compounds at 10 μM were calculated relative to the inhibition percentage by T140 (100%).

^e EC₅₀ values are the concentrations for 50% protection from X4-HIV-1 (NL4-3 strain)-induced cytopathogenicity in MT-4 cells.

^f CC₅₀ values are the concentrations for 50% reduction of the viability of MT-4 cells. All data are the mean values from at least three independent experiments.

significant anti-HIV activity at concentrations below 11 μM because of high cytotoxicity (CC₅₀ = 11 μM). With the exception of **27**, **30**, **42** and **43**, the tested compounds showed no significant cytotoxicity (CC₅₀ > 20 μM, Table 1). On the other hand, compounds **26**, **27**, **33**, **34** and **35** at concentrations below 100 μM failed to show significant protective activity against macrophage-tropic (R5-) HIV-1 (NL(AD8) strain)-induced cytopathogenicity in PM-1/CCR5, whereas the EC₅₀ of the CCR5 antagonist SCH-D¹⁷ in this assay was 0.055 μM (data not shown). Since instead of CXCR4, R5-HIV-1 strains use the chemokine receptor CCR5, a member of the GPCR family, as the major co-receptor for their entry, this suggests that these compounds do not bind to CCR5. Thus, compounds **26**, **27**, **33**, **34** or **35** have highly selective affinity for CXCR4. Compounds **34** and **35**, which have significant anti-HIV activity, have a pyridyl group with a nitrogen atom at the γ-position, in contrast to compounds **26**, **27** and **33** which also show CXCR4-binding activity, but have a pyridyl group with a nitrogen atom at the β-position. Furthermore, compounds **34** and **35** have R¹ = 4-fluorobenzyl and R² = (S)-1-naphthylethylamine. A possible explanation of these observations is that compounds **34** and **35** compete with HIV-1 in binding to CXCR4 while compounds **26** and **33** compete with HIV-1 and CXCL12. Compound **27** does not compete with HIV-1 because of its high cytotoxicity. This suggests that the CXCR4 binding site used by compounds **34** and **35** differs slightly from that used by compounds **26**, **27** and **33**.

Low molecular weight CXCR4 ligands with two types of recognition modes for CXCR4 have been obtained in this study: one causes competition with HIV-1 on CXCR4 whereas the other causes competition with HIV-1 and CXCL12. These compounds have selective affinity for CXCR4 because they do not significantly bind to CCR5. Further structural modification studies of these CXCR4 ligands are the subject of an ongoing project.

Acknowledgements

This work was supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science,

and Technology of Japan, Japan Human Science Foundation, and Health and Labour Sciences Research Grants from Japanese Ministry of Health, Labor, and Welfare. T.T. and C.H. are grateful for the JSPS Research Fellowships for Young Scientists.

References and notes

- (a) Nagasawa, T.; Kikutani, H.; Kishimoto, T. *Proc. Natl. Acad. Sci. U. S. A.* **1994**, *91*, 2305; (b) Bleul, C. C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T. A. *Nature* **1996**, *382*, 829; (c) Oberlin, E.; Amara, A.; Bachelier, F.; Bessia, C.; Virelizier, J. L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J. M.; Clark-Lewis, I.; Legler, D. L.; Loetscher, M.; Baggiolini, M.; Moser, B. *Nature* **1996**, *382*, 833; (d) Tashiro, K.; Tada, H.; Heilker, R.; Shirozu, M.; Nakano, T.; Honjo, T. *Science* **1993**, *261*, 600.
- Bleul, C. C.; Fuhrbrigge, R. C.; Casanovas, J. M.; Aiuti, A.; Springer, T. A. *J. Exp. Med.* **1996**, *2*, 1101.
- (a) Tachibana, K.; Hirota, S.; Iizasa, H.; Yoshida, H.; Kawabata, K.; Kataoka, Y.; Kitamura, Y.; Matsushima, K.; Yoshida, N.; Nishikawa, S.; Kishimoto, T.; Nagasawa, T. *Nature* **1998**, *393*, 591; (b) Nagasawa, T.; Hirota, S.; Tachibana, K.; Takakura, N.; Nishikawa, S.; Kitamura, Y.; Yoshida, N.; Kikutani, H.; Kishimoto, T. *Nature* **1996**, *382*, 635.
- (a) Zhu, Y.; Yu, Y.; Zhang, X. C.; Nagasawa, T.; Wu, J. Y.; Rao, Y. *Nat. Neurosci.* **2002**, *5*, 719; (b) Stumm, R. K.; Zhou, C.; Ara, T.; Lazarini, F.; Dubois-Dalq, M.; Nagasawa, T.; Holt, V.; Schulz, S. *J. Neurosci.* **2003**, *23*, 5123.
- (a) Deng, H. K.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Marzio, P. D.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. *Nature* **1996**, *381*, 661; (b) Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. *Science* **1996**, *272*, 872.
- (a) Koshiba, T.; Hosotani, R.; Miyamoto, Y.; Ida, J.; Tsuji, S.; Nakajima, S.; Kawaguchi, M.; Kobayashi, H.; Doi, R.; Hori, T.; Fujii, N.; Imamura, M. *Clin. Cancer Res.* **2000**, *6*, 3530; (b) Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; Barrera, J. L.; Mohar, A.; Verastegui, E.; Zlotnik, A. *Nature* **2001**, *410*, 50; (c) Tamamura, H.; Hori, A.; Kanzaki, N.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. *FEBS Lett.* **2003**, *550*, 79.
- (a) Tsukada, N.; Burger, J. A.; Zvaifler, N. J.; Kipps, T. J. *Blood* **2002**, *99*, 1030; (b) Juarez, J.; Bradstock, K. F.; Gottlieb, D. J.; Bendall, L. J. *Leukemia* **2003**, *17*, 1294.
- (a) Nanki, T.; Hayashida, K.; El-Gabalawy, H. S.; Suson, S.; Shi, K.; Girschick, H. J.; Yavuz, S.; Lipsky, P. E. *J. Immunol.* **2000**, *165*, 6590; (b) Tamamura, H.; Fujisawa, M.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. *FEBS Lett.* **2004**, *569*, 99.
- (a) Murakami, T.; Nakajima, T.; Koyanagi, Y.; Tachibana, K.; Fujii, N.; Tamamura, H.; Toshida, N.; Waki, M.; Matsumoto, A.; Yoshie, O.; Kishimoto, T.; Yamamoto, N.; Nagasawa, T. *J. Exp. Med.* **1997**, *186*, 1389; (b) Tamamura, H.; Xu, Y.; Hattori, T.; Zhang, X.; Arakaki, R.; Kanbara, K.; Omagari, A.; Otaka, A.; Ibuka, T.; Yamamoto, N.; Nakashima, H.; Fujii, N. *Biochem. Biophys. Res.*

- Commun.* **1998**, 253, 877; (c) Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. *Bioorg. Med. Chem. Lett.* **2000**, 10, 2633; (d) Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J. A.; Trent, J. O.; Wang, Z.; Peiper, S. C. *Angew. Chem., Int. Ed.* **2003**, 42, 3251; (e) Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. *J. Med. Chem.* **2005**, 48, 380; (f) Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka, A.; Fujii, N. *J. Med. Chem.* **2005**, 48, 3280; (g) Hashimoto, C.; Tanaka, T.; Narumi, T.; Nomura, W.; Tamamura, H. *Expert Opin. Drug Disc.* **2011**, 6, 1067.
- Tamamura, H.; Tsutsumi, H.; Masuno, H.; Mizokami, S.; Hiramatsu, K.; Wang, Z.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Fujii, N. *Org. Biomol. Chem.* **2006**, 4, 2354.
 - Schols, D.; Struyf, S.; Van Damme, J.; Este, J. A.; Henson, G.; DeClarcq, E. *J. Exp. Med.* **1997**, 186, 1383.
 - Ichiyama, K.; Yokoyama-Kumakura, S.; Tanaka, Y.; Tanaka, R.; Hirose, K.; Bannai, K.; Edamatsu, T.; Yanaka, M.; Niitani, Y.; Miyano-Kurosaki, N.; Takaku, H.; Koyanagi, Y.; Yamamoto, N. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, 100, 4185.
 - Tamamura, H.; Ojida, A.; Ogawa, T.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Hamachi, I.; Fujii, N. *J. Med. Chem.* **2006**, 49, 3412.
 - Tanaka, T.; Narumi, T.; Ozaki, T.; Sohma, A.; Ohashi, N.; Hashimoto, C.; Itotani, K.; Nomura, W.; Murakami, T.; Yamamoto, N.; Tamamura, H. *ChemMedChem* **2011**, 6, 834.
 - For example, the synthesis of compound **30**: To a stirred solution of **8Ai** (176 mg, 0.415 mmol, HCl salt) in DMF (4 mL) were added EDCI·HCl (104 mg, 0.454 mmol), HOBt·H₂O (58.4 mg, 0.381 mmol), Et₃N (301 μL, 2.16 mmol) and (**5**)-**11** (320 mg, 0.657 mmol, HCl salt) at 0 °C. The mixture was stirred at room temperature for 43 h. The reaction mixture was diluted with CHCl₃ and washed with saturated citric acid, saturated NaHCO₃ and brine, and dried over MgSO₄. Concentration under reduced pressure followed by flash column chromatography over silica gel with CHCl₃/MeOH (20/1) gave the condensation product (175 mg, 0.208 mmol, 50% yield) as white powder. To this compound were added *m*-cresol (75.0 μL, 0.714 mmol), 1,2-ethanedithiol (225 μL, 2.68 mmol), thioanisole (225 μL, 1.91 mmol), TFA (3 mL) and bromotrimethylsilane (495 μL, 3.82 mmol) with stirring at 0 °C, and the stirring was continued at room temperature for 3.5 h under N₂. The reaction mixture was concentrated under reduced pressure, followed by addition of Et₂O to precipitate the product. After washing with Et₂O, the crude product was purified by preparative HPLC and lyophilized to give the compound **30** (15.6 mg, 0.0236 mmol, 13%) as white powder. ¹H NMR δ_H (400 MHz; DMSO-*d*₆) 1.49 (m, 2H), 1.51 (d, *J* = 7.2 Hz, 3H), 1.80–1.62 (m, 2H), 3.07 (dd, *J* = 6.4, 12.8 Hz, 2H), 3.85 (s, 2H), 3.91 (s, 4H), 4.54 (m, 1H), 5.72 (m, 1H), 7.13 (t, *J* = 8.8 Hz, 2H), 7.40 (m, 1H), 7.60–7.45 (m, 10H), 7.75–7.95 (m, 5H), 8.10 (m, 1H), 8.40 (d, *J* = 8.0 Hz, 1H), 8.58 (m, 1H), 8.65 (d, *J* = 7.6 Hz, 1H); LRMS (ESI), *m/z* calcd for C₃₉H₄₂FN₇O₂ (MH)⁺ 660.34, found 660.31.
 - Tanaka, T.; Tsutsumi, H.; Nomura, W.; Tanabe, Y.; Ohashi, N.; Esaka, A.; Ochiai, C.; Sato, J.; Itotani, K.; Murakami, T.; Ohba, K.; Yamamoto, N.; Fujii, N.; Tamamura, H. *Org. Biomol. Chem.* **2008**, 6, 4374.
 - Tagat, J. R.; McCombie, S. W.; Nazareno, D.; Labroli, M. A.; Xiao, Y.; Steensma, R. W.; Strizki, J. M.; Baroudy, B. M.; Cox, K.; Lachowicz, J.; Varty, G.; Watkins, R. J. *Med. Chem.* **2004**, 47, 2405.

